Lupin Pharmaceuticals Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Lupin Pharmaceuticals Inc Pharmaceutical Import Records from India — 2 Products, $373.1K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Lupin Pharmaceuticals Inc — Pharmaceutical Importer Profile (2026) | 2 Products, $373.1K Trade | TransData Nexus

Lupin Pharmaceuticals Inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $373.1K Total Trade · DGFT Verified

Lupin Pharmaceuticals Inc is a pharmaceutical importer based in United States with a total trade value of $373.1K across 2 products in 2 therapeutic categories. Based on 9 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Lupin Pharmaceuticals Inc sources from 1 verified Indian supplier, with Lupin Limited accounting for 100.0% of imports.

Lupin Pharmaceuticals Inc — Import Portfolio & Supplier Network

Lupin Pharmaceuticals Inc import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Lupin Pharmaceuticals Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Lupin Limited	$2.7M	62	100.0%

Lupin Pharmaceuticals Inc sources from 1 verified Indian supplier across 48 distinct formulations. The sourcing is highly concentrated — Lupin Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Lupin Pharmaceuticals Inc Import?

Formulation	Value	Ships
Turqoz 0.3MG/0.03mg3x28 TAB	$194.2K	4
Leflunomide TAB 20MG x 30's	$139.1K	4
Sertraline TAB USP 50MG-500'sus	$100.0K	2
Norethindrone tabs USP 0.35MG	$100.0K	2
Dros&ee TAB USP 3/0.03MG 3x28s_eq	$100.0K	2
Ng&ee0.18/.035.215/.035&.25/.035mg28_us	$78.3K	2
Betamethasone dipropionate	$75.5K	2
Clobetasol propionate ointment .05 x	$70.0K	2
Fluocinonide topical solution 0.05 x	$66.5K	2
Lisinopril TAB USP 40MG-1000'sus r2	$50.0K	1
Metformin hcl er tabs 1000MG-90's us	$50.0K	1
Metformin hcl er tabs 1000MG-90's us	$50.0K	1
Ethambutol hcl TAB USP 400MG-100'sus	$50.0K	1
Ethacrynic acid tabs USP 25MG x 100's	$50.0K	1
Darunavir ethanolate TAB 800 MG 30 usa	$50.0K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lisinopril	Cardiovascular	$200.0K	4	0.3%	7
2	Leflunomide	Immunosuppressants	$173.1K	5	1.2%	20

Lupin Pharmaceuticals Inc imports 2 pharmaceutical products across 2 categories into United States totaling $373.1K.

Lupin Pharmaceuticals Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Lupin Pharmaceuticals Inc. is the U.S. subsidiary of Lupin Limited, a global pharmaceutical leader headquartered in Mumbai, India. Established in 2003, Lupin Pharmaceuticals Inc. is dedicated to delivering high-quality, branded and generic medications trusted by healthcare professionals and patients across geographies. The company has a significant presence in the U.S. market, ranking as the third-largest pharmaceutical company by prescriptions. Lupin Pharmaceuticals Inc. operates in various therapeutic areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women's health.

2Distribution Network

Lupin Pharmaceuticals Inc. has a well-established distribution network across the United States, with its headquarters located in Naples, Florida. The company also maintains corporate offices in Bridgewater, New Jersey, and research and manufacturing facilities in Coral Springs, Florida, and Somerset, New Jersey. This strategic geographic presence enables Lupin to efficiently manage its logistics and supply chain operations, ensuring timely delivery of pharmaceutical products to meet market demand.

3Industry Role

Lupin Pharmaceuticals Inc. plays a pivotal role in the U.S. pharmaceutical supply chain as a primary wholesaler and distributor. The company imports a diverse range of pharmaceutical formulations from its parent company, Lupin Limited, in India, and other global suppliers. By leveraging its extensive distribution network and manufacturing capabilities, Lupin Pharmaceuticals Inc. ensures the availability of essential medications across the United States, thereby contributing significantly to the healthcare sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Lupin Pharmaceuticals Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Lupin Pharmaceuticals Inc. demonstrates a high degree of supplier concentration, with a total import value of $373,000 USD from India over nine shipments, all sourced from a single supplier, Lupin Limited. This single-source dependency indicates a strategic choice to maintain a streamlined supply chain and ensure consistent product quality. The shipment data reveals a stable and reliable relationship between Lupin Pharmaceuticals Inc. and Lupin Limited, suggesting effective collaboration and mutual trust. However, this concentration also exposes the company to potential risks associated with supply chain disruptions, such as production delays or regulatory challenges in the supplier's country.

2Supply Chain Resilience

The resilience of Lupin Pharmaceuticals Inc.'s Indian supply chain is bolstered by its exclusive partnership with Lupin Limited, a leading pharmaceutical manufacturer with a robust portfolio of 48 unique formulations. This extensive product range provides a level of diversification that can mitigate risks associated with single-source dependency. Additionally, Lupin Limited's adherence to international quality standards and regulatory compliance enhances the reliability of the supply chain. However, the lack of backup suppliers and potential exposure to shipping route disruptions could impact the supply chain's resilience.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which sets forth requirements for drug safety, efficacy, and quality. The FDA's Center for Drug Evaluation and Research (CDER) is responsible for evaluating and approving new drugs, including generics, ensuring they meet the agency's standards before entering the U.S. market. For Indian generics, the FDA's Abbreviated New Drug Application (ANDA) process allows for the approval of generic drugs based on their bioequivalence to existing branded drugs.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. involve obtaining FDA approval through the ANDA process, which includes demonstrating bioequivalence to the reference listed drug. Good Manufacturing Practice (GMP) certification is crucial, with the FDA recognizing certifications from international bodies such as the European Union's GMP, the World Health Organization's GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Wholesale distribution authorization is also required, ensuring that distributors comply with federal and state regulations governing the storage, handling, and distribution of pharmaceutical products.

Lupin Pharmaceuticals Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Lupin Pharmaceuticals Inc.'s focus on importing cardiovascular and immunosuppressant medications aligns with the company's strategic emphasis on therapeutic areas with high unmet medical needs. The significant market demand for these products drives the imports, as they are essential for managing chronic conditions and preventing organ rejection in transplant patients. By concentrating on these therapeutic categories, Lupin Pharmaceuticals Inc. aims to enhance patient outcomes and strengthen its position in the U.S. pharmaceutical market.

2Sourcing Profile

Lupin Pharmaceuticals Inc. employs a sourcing strategy that prioritizes high-quality generic drugs, particularly in the cardiovascular and immunosuppressant categories. The company's exclusive partnership with Lupin Limited allows for a consistent supply of these formulations, leveraging India's manufacturing capabilities and cost advantages. This strategy enables Lupin Pharmaceuticals Inc. to offer affordable and effective treatment options to U.S. patients, while maintaining a competitive edge in the market.

3Market Positioning

Based on its product mix, Lupin Pharmaceuticals Inc. serves a diverse segment of the U.S. market, including retail pharmacies, hospitals, government tenders, and wholesale distribution. The company's focus on essential medications in high-demand therapeutic areas positions it to meet the needs of various healthcare providers and patients, ensuring broad accessibility to its products across the country.

Seller's Guide — How to Become a Supplier to Lupin Pharmaceuticals Inc

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to enter Lupin Pharmaceuticals Inc.'s supply chain, provided they can offer unique formulations, competitive pricing, and adherence to international quality standards. Gaps in Lupin Pharmaceuticals Inc.'s current sourcing include potential diversification of suppliers to mitigate risks associated with single-source dependency. New suppliers can capitalize on these opportunities by demonstrating reliability, compliance with regulatory requirements, and the ability to meet market demand.

2Requirements & Qualifications

Indian exporters seeking to supply Lupin Pharmaceuticals Inc. and the U.S. market must obtain FDA approval through the ANDA process, ensuring bioequivalence to reference listed drugs. They must also possess GMP certifications recognized by the FDA, such as EU GMP, WHO GMP, or PIC/S. Additionally, compliance with U.S. labeling requirements, including English language labeling and serialization mandates, is essential. Exporters must also adhere to FDA regulations governing the importation and distribution of pharmaceutical products.

3How to Approach

Frequently Asked Questions — Lupin Pharmaceuticals Inc

What products does Lupin Pharmaceuticals Inc import from India?

Lupin Pharmaceuticals Inc imports 2 pharmaceutical products across 2 categories. Top imports: Lisinopril ($200.0K), Leflunomide ($173.1K).

Who supplies pharmaceuticals to Lupin Pharmaceuticals Inc from India?

Lupin Pharmaceuticals Inc sources from 1 verified Indian suppliers. The primary supplier is Lupin Limited (100.0% of imports, $2.7M).

What is Lupin Pharmaceuticals Inc's total pharmaceutical import value?

Lupin Pharmaceuticals Inc's total pharmaceutical import value from India is $373.1K, based on 9 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Lupin Pharmaceuticals Inc focus on?

Lupin Pharmaceuticals Inc imports across 2 categories. The largest: Cardiovascular (53.6%), Immunosuppressants (46.4%).

Get Full Lupin Pharmaceuticals Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.